Takeda Pharmaceutical Company Limited
TAK
$15.91
$0.261.66%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.88% | 3.07% | -4.63% | -1.13% | -2.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.88% | 3.07% | -4.63% | -1.13% | -2.36% |
| Cost of Revenue | 15.85% | -4.78% | -2.85% | 7.28% | -6.13% |
| Gross Profit | -10.06% | 7.57% | -5.53% | -5.10% | -0.16% |
| SG&A Expenses | -5.85% | 3.42% | -4.75% | 2.27% | 1.02% |
| Depreciation & Amortization | -27.34% | 0.42% | -4.61% | 0.68% | -0.63% |
| Other Operating Expenses | 28.01% | -52.60% | 136.67% | -87.81% | 21.81% |
| Total Operating Expenses | -0.89% | -7.12% | 1.86% | -2.44% | 1.94% |
| Operating Income | -0.82% | 952.52% | -29.52% | 5.84% | -27.01% |
| Income Before Tax | -304.54% | 401.64% | -76.21% | 19.00% | -119.93% |
| Income Tax Expenses | -1,866.82% | 1,059.27% | 47.50% | -31.15% | 90.81% |
| Earnings from Continuing Operations | -240.88% | 330.67% | -112.84% | 40.74% | -3,254.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.77% | -102.22% | -18.96% | 23.81% | -131.29% |
| Net Income | -240.75% | 331.11% | -112.92% | 40.77% | -3,229.30% |
| EBIT | -0.82% | 952.52% | -29.52% | 5.84% | -27.01% |
| EBITDA | -10.34% | -9.20% | -17.86% | 3.90% | 135.71% |
| EPS Basic | -241.07% | 332.93% | -112.96% | 41.16% | -3,192.31% |
| Normalized Basic EPS | -39.86% | 342.27% | -33.80% | 2.92% | -20.28% |
| EPS Diluted | -241.07% | 325.71% | -113.18% | 40.82% | -3,192.31% |
| Normalized Diluted EPS | -39.86% | 338.30% | -32.68% | 2.69% | -20.28% |
| Average Basic Shares Outstanding | -0.10% | -0.39% | -0.34% | -0.27% | 0.84% |
| Average Diluted Shares Outstanding | -0.10% | 1.28% | -1.99% | -0.06% | 0.84% |
| Dividend Per Share | -2.66% | -- | 2.85% | -- | 1.56% |
| Payout Ratio | 0.75% | -0.76% | -8.45% | -0.19% | 0.97% |